2m 2m 2m 2m 2m 2m 2m
- $427.5MMarket Cap
- -70.58%1-Year Change
- BiotechnologyIndustry
INDAPTUS THRP (INDP)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 71
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders
Abbott Cooper PLLC is investigating potential fiduciary duty violations by the board of Indaptus Therapeutics in connection with a private placement of preferred stock. The investigation targets stockholders who held shares prior to December 22, 2025.
06/17/2026, 11:02 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/23/2026
Company Profile
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Key Executives
- Walt Addison Linscott
- Michael J. Newman
- Junyi Dai
- Yu Ding
Current Ownership Distribution
- Insiders93.9M (86.36%)
- Institutions11.0M (10.16%)
- Mutual Funds3.8M (3.48%)
- Other0 (0.00%)